コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 therapy (which often included balloon aortic valvuloplasty).
2 ry (bioprosthesis replacement, valve repair, valvuloplasty).
3 ten benefit from percutaneous balloon mitral valvuloplasty.
4 onse to the transient hypotension induced by valvuloplasty.
5 re and 20 to 30 min after undergoing balloon valvuloplasty.
6 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty.
7 atheter aortic valve implantation or balloon valvuloplasty.
8 tricular (BV) circulation after fetal aortic valvuloplasty.
9 valve replacement (TAVR), and balloon aortic valvuloplasty.
10 s, TAVI was performed without aortic balloon valvuloplasty.
11 may become the standard approach for mitral valvuloplasty.
12 fants and neonates is trans-catheter balloon valvuloplasty.
13 ented in any of the patients after tricuspid valvuloplasty.
14 eatment, which often included balloon aortic valvuloplasty.
15 ion were assessed before and after tricuspid valvuloplasty.
16 unction both at baseline and after tricuspid valvuloplasty.
17 moderate MR tended to improve without mitral valvuloplasty.
19 e), an additional 86 aortic and 16 pulmonary valvuloplasties, 37 atrial septal cases, and 6 unclassif
21 lts are obtained with trans-catheter balloon valvuloplasty, although stenosis resistant to further ba
22 and therapeutic purposes, including balloon valvuloplasties and electrophysiologic ablation procedur
23 al among patients who underwent fetal aortic valvuloplasty and achieved a BV circulation postnatally
24 dy sought to compare outcomes after surgical valvuloplasty and balloon dilation of the aortic valve i
28 long-term studies of trans-catheter balloon valvuloplasty and surgical valvotomy warrant a review of
29 is, having the relief of stenosis by balloon valvuloplasty and undergoing initial treatment as a neon
30 tral valvuloplasty, antegrade balloon aortic valvuloplasty, and ablation of arrhythmias in the LA.
33 ion of the ductus arteriosus, balloon aortic valvuloplasty, and stenting or angioplasty of Blalock-Ta
36 formed for procedures such as balloon mitral valvuloplasty, antegrade balloon aortic valvuloplasty, a
37 of patent ductus arteriosus (PDA); pulmonary valvuloplasty; aortic valvuloplasty; coarctation of the
38 ng a surgical AV procedure or aortic balloon valvuloplasty at Children's Hospital of Oklahoma between
39 g mid-term and long-term results for balloon valvuloplasty, balloon atrial septostomy and pulmonary a
40 (AoV) surgery after neonatal balloon aortic valvuloplasty (BAV) and characterize clinical outcomes o
43 unexpected death (SUD) after balloon aortic valvuloplasty (BAVP) for congenital aortic stenosis (AS)
45 tion in LV pressure load with balloon aortic valvuloplasty (BAVP) may improve diastolic function.
48 nts for congenital MS include balloon mitral valvuloplasty (BMVP), surgical mitral valvuloplasty (SMV
51 iosus (PDA); pulmonary valvuloplasty; aortic valvuloplasty; coarctation of the aorta angioplasty and
57 2008, 70 fetuses underwent attempted aortic valvuloplasty for critical aortic stenosis with evolving
58 icular versus biventricular) of fetal aortic valvuloplasty for fetal aortic stenosis with evolving HL
59 uded 100 patients who underwent fetal aortic valvuloplasty for severe midgestation aortic stenosis wi
63 cases entered, 245 underwent FCI: 100 aortic valvuloplasties from a previous single-center report (ex
67 ays, mortality in the medical/balloon aortic valvuloplasty group was 102 (37.2%), and during median f
68 had experienced less previous balloon aortic valvuloplasty, had higher left ventricular ejection frac
73 umented improved outcomes following surgical valvuloplasty in a subset of patients who achieve tri-le
74 es increased in size after balloon pulmonary valvuloplasty in both groups at a rate that paralleled o
77 etermine (1) whether V O2 is increased after valvuloplasty in patients with mitral stenosis, and (2)
82 ere aortic and pulmonary stenoses by balloon valvuloplasty may diminish their postnatal expression.
86 n fetuses underwent pre-natal cardiac aortic valvuloplasty (n = 8) and/or atrial septal dilation/sten
87 ction (n=9), arch augmentation (n=5), mitral valvuloplasty (n=5), ventricular septal defect closure (
88 d in 51 patients, including aortic valvotomy/valvuloplasty (n=56), coarctation repair (n=21), subaort
92 o standard therapy (including balloon aortic valvuloplasty) or transfemoral transcatheter implantatio
101 he NHLBI established the multicenter Balloon Valvuloplasty Registry in November 1987 to assess both s
105 nction was assessed as fair before tricuspid valvuloplasty repair and improved to good in five of sev
107 intervention vs. traditional balloon aortic valvuloplasty; shunt type in staged palliation for hypop
108 mitral valvuloplasty (BMVP), surgical mitral valvuloplasty (SMVP), and mitral valve replacement (MVR)
110 greater improvements in cardiac output after valvuloplasty than do patients with aortic stenosis, the
111 term results of transcatheter balloon aortic valvuloplasty, the preferred treatment for congenital ao
112 surgery; the benefit of percutaneous balloon valvuloplasty to mortality might be similar to that of s
113 physiology, lack of prior balloon pulmonary valvuloplasty, use of drug-eluting stent, and increased